In a phase 2/3 trial of 3,732 minors from 12 to 17 years in the United States, blood tests showed that Moderna’s covid-19 vaccine produced an immune response that was equivalent to previous findings in adults.
The company did not provide a percentage of efficacy, as the trial was not designed to specifically examine that parameter.
However, initial observations found that none of the children who received the vaccine became ill with COVID-19 starting 14 days after their second dose.
Covid-19 vaccine does not affect development of the youngest
Four of the children who received the placebo tested positive for COVID-19, which Moderna says is “consistent with 100% vaccine efficacy.” The company notes that the figure could change as more data is collected.
Moderna also reviewed how well the vaccine worked after just a single dose. The results suggest that after one dose, the vaccine was 93% effective in prevent mild cases of covid-19, with a single symptom instead of two or more symptoms.
Moderna announced the results Tuesday in a press release, and the results have not yet been reviewed or published by peers.
The company said the vaccine was “generally well tolerated” and no significant safety issues have been identified.
Side effects, including headache, fatigue, muscle pain, and chills, were detected after administration of the second dose. Pain was also observed at the injection site.
Is a baby immunized through its vaccinated mother?
Moderna says it plans to submit the results to the US Food and Drug Administration in early June along with an application for authorization to use the vaccine in adolescents. He also plans to submit the data to a peer-reviewed publication.
The vaccine Moderna is now licensed for use by people over 18 years. Another covid-19 vaccine, manufactured by Pfizer / BioNTech, is licensed for use in people 12 years of age and older.